Visen Pharmaceuticals, An Innovative Biopharmaceutical Company Focused On Endocrine Diseases, Has Announced For The First Time Detailed Clinical Data From Its Pivotal Phase 3 Study Of Lonapegsomatropin, A Long-Acting Prodrug Of Unmodified Somatropin Being Investigated As A Once-Weekly Injection In Children With Growth Hormone Deficiency (Ghd) In China.The Data Showed That Lonapegsomatropin Demonstrated An Annualized Height Velocity (Ahv) Of 10.66 Cm/Year Compared To 9.75 Cm/Year For The Daily Hgh At 52 Weeks (Treatment Difference At 0.91 Cm/Year With A 95 Per Cent Confidence Interval: 0.37
